Skip to main navigation Skip to search Skip to main content

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study

  • Johan A. Maertens
  • , George R. Thompson
  • , Andrej Spec
  • , Fariba M. Donovan
  • , Sarah P. Hammond
  • , Anke H.W. Bruns
  • , Galia Rahav
  • , Shmuel Shoham
  • , Royce Johnson
  • , Bart Rijnders
  • , Joanna Schaenman
  • , Martin Hoenigl
  • , C. Orla Morrissey
  • , Sanjay R. Mehta
  • , Christopher H. Heath
  • , Philipp Koehler
  • , David L. Paterson
  • , Monica A. Slavin
  • , Jesus Fortún
  • , M. Hong Nguyen
    • Thomas F. Patterson, Olga Uspenskaya, Frank L. Van de Veerdonk, Paul E. Verweij, Mickael Aoun, Aspasia Georgala, Barbara D. Alexander, Methee Chayakulkeeree, Varun Mehra, Marisa H. Miceli, Monica K. Sikka, Amparo Solé, Thomas J. Walsh, Jose Maria Aguado, Steven M. Holland, Mohamed Moussa, Riina Rautemaa-Richardson, Rohit Bazaz, Stefan Schwartz, Stephen R. Walsh, Markus Plate, Dana Yehudai-Ofir, Roger J. Brüggemann, Oliver A. Cornely, Luis Ostrosky-Zeichner, Jose A. Vazquez, P. Lewis White, Karen Cornelissen, Geoffrey G. Ross, Lesley Fitton, Aaron Dane, Daniela Zinzi, John H. Rex, Sharon C.A. Chen

Research output: Contribution to journal › Article › peer-review

79 Scopus citations

Fingerprint

Dive into the research topics of 'Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science